Foundation Medicine Stock Price, News & Analysis (NASDAQ:FMI)

$74.90 +5.95 (+8.63 %)
(As of 02/18/2018 05:39 AM ET)
Previous Close$74.90
Today's Range$69.15 - $74.95
52-Week Range$22.40 - $75.20
Volume385,149 shs
Average Volume250,976 shs
Market Capitalization$2.72 billion
P/E RatioN/A
Dividend YieldN/A
Beta-0.03

About Foundation Medicine (NASDAQ:FMI)

Foundation Medicine logoFoundation Medicine, Inc. is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. It is engaged in the business of delivering molecular information about cancer to its customers. Its platform includes various methods and algorithms for analyzing specimens across various types of cancer. Its suite of clinical molecular information products includes FoundationOne, which is used for solid tumors; FoundationOne Heme, which is used for blood-based cancers or hematologic malignancies, including leukemia, lymphoma, myeloma, pediatric cancers and advanced sarcoma; FoundationACT (Assay for Circulating Tumor DNA), which is a blood-based (liquid biopsy) assay that evaluates circulating tumor deoxyribonucleic acid (ctDNA), and FoundationFocus CDxBRCA, which is a companion diagnostic assay to aid in identifying women with ovarian cancer for whom treatment with Rubraca (rucaparib).

Receive FMI News and Ratings via Email

Sign-up to receive the latest news and ratings for FMI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:FMI
CUSIPN/A
Phone617-418-2200

Debt

Debt-to-Equity Ratio0.47%
Current Ratio2.24%
Quick Ratio2.03%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$116.86 million
Price / Sales23.23
Cash FlowN/A
Price / CashN/A
Book Value$4.70 per share
Price / Book15.94

Profitability

Trailing EPS($4.47)
Net Income$-113,190,000.00
Net Margins-119.69%
Return on Equity-143.18%
Return on Assets-93.58%

Miscellaneous

Employees535
Outstanding Shares36,250,000

Foundation Medicine (NASDAQ:FMI) Frequently Asked Questions

What is Foundation Medicine's stock symbol?

Foundation Medicine trades on the NASDAQ under the ticker symbol "FMI."

How were Foundation Medicine's earnings last quarter?

Foundation Medicine Inc (NASDAQ:FMI) released its quarterly earnings data on Wednesday, November, 1st. The company reported ($0.90) EPS for the quarter, beating the Zacks' consensus estimate of ($1.06) by $0.16. The company earned $42.66 million during the quarter, compared to the consensus estimate of $37.99 million. Foundation Medicine had a negative net margin of 119.69% and a negative return on equity of 143.18%. Foundation Medicine's quarterly revenue was up 45.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.90) EPS. View Foundation Medicine's Earnings History.

When will Foundation Medicine make its next earnings announcement?

Foundation Medicine is scheduled to release their next quarterly earnings announcement on Wednesday, March, 7th 2018. View Earnings Estimates for Foundation Medicine.

Where is Foundation Medicine's stock going? Where will Foundation Medicine's stock price be in 2018?

5 analysts have issued twelve-month target prices for Foundation Medicine's stock. Their predictions range from $31.00 to $90.00. On average, they expect Foundation Medicine's share price to reach $58.25 in the next twelve months. View Analyst Ratings for Foundation Medicine.

Who are some of Foundation Medicine's key competitors?

Who are Foundation Medicine's key executives?

Foundation Medicine's management team includes the folowing people:

  • Michael J. Pellini M.D., Chairman of the Board (Age 52)
  • Steven J. Kafka Ph.D., President, Chief Operating Officer (Age 47)
  • Troy Cox, President, Chief Executive Officer, Director (Age 53)
  • Jason Ryan, Chief Financial Officer, Principal Financial Officer, Principal Accounting officer (Age 42)
  • Robert Hesslein, Senior Vice President, General Counsel (Age 63)
  • Tom Civik, Chief Commercial Officer (Age 48)
  • Vincent Miller M.D., Chief Medical Officer (Age 55)
  • Alexis Borisy, Director (Age 45)
  • Daniel O. Day, Director (Age 52)
  • Michael R. Dougherty, Director (Age 59)

Who owns Foundation Medicine stock?

Foundation Medicine's stock is owned by many different of retail and institutional investors. Top institutional investors include Gilder Gagnon Howe & Co. LLC (4.15%), BlackRock Inc. (3.90%), Chevy Chase Trust Holdings Inc. (2.95%), Oppenheimer & Co. Inc. (1.97%), Alliancebernstein L.P. (0.84%) and Peregrine Capital Management LLC (0.78%). Company insiders that own Foundation Medicine stock include David Daly, Evan/ Fa Jones, Jason Ryan, Krishna Yeshwant, Michael J Pellini, Robert W Hesslein, Steven J Kafka, Troy Cox and Vincent A Miller. View Institutional Ownership Trends for Foundation Medicine.

Who sold Foundation Medicine stock? Who is selling Foundation Medicine stock?

Foundation Medicine's stock was sold by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., Pier Capital LLC, Amundi Pioneer Asset Management Inc., ARK Investment Management LLC, Peregrine Capital Management LLC, Platinum Investment Management Ltd., BlackRock Inc. and Gilder Gagnon Howe & Co. LLC. Company insiders that have sold Foundation Medicine company stock in the last year include David Daly, Evan/ Fa Jones, Jason Ryan, Krishna Yeshwant, Michael J Pellini, Robert W Hesslein, Steven J Kafka, Troy Cox and Vincent A Miller. View Insider Buying and Selling for Foundation Medicine.

Who bought Foundation Medicine stock? Who is buying Foundation Medicine stock?

Foundation Medicine's stock was purchased by a variety of institutional investors in the last quarter, including Boston Advisors LLC, Advisory Research Inc., Bain Capital Public Equity Management LLC, Two Sigma Investments LP, First Trust Advisors LP, Millennium Management LLC, Castleark Management LLC and Geode Capital Management LLC. View Insider Buying and Selling for Foundation Medicine.

How do I buy Foundation Medicine stock?

Shares of Foundation Medicine can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Foundation Medicine's stock price today?

One share of Foundation Medicine stock can currently be purchased for approximately $74.90.

How big of a company is Foundation Medicine?

Foundation Medicine has a market capitalization of $2.72 billion and generates $116.86 million in revenue each year. The company earns $-113,190,000.00 in net income (profit) each year or ($4.47) on an earnings per share basis. Foundation Medicine employs 535 workers across the globe.

How can I contact Foundation Medicine?

Foundation Medicine's mailing address is 150 Second Street, Cambridge MA, 02141. The company can be reached via phone at 617-418-2200 or via email at [email protected]


MarketBeat Community Rating for Foundation Medicine (FMI)

Community Ranking:  1.5 out of 5 (star half star)
Outperform Votes:  114 (Vote Outperform)
Underperform Votes:  269 (Vote Underperform)
Total Votes:  383
MarketBeat's community ratings are surveys of what our community members think about Foundation Medicine and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Foundation Medicine (NASDAQ:FMI) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.602.672.672.50
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $58.25$35.00$35.00$35.00
Price Target Upside: 11.20% downside5.42% upside5.42% upside5.42% upside

Foundation Medicine (NASDAQ:FMI) Consensus Price Target History

Price Target History for Foundation Medicine (NASDAQ:FMI)

Foundation Medicine (NASDAQ:FMI) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/15/2018CowenInitiated CoverageOutperform$90.00MediumView Rating Details
1/29/2018Goldman Sachs GroupInitiated CoverageNeutral -> Neutral$73.00LowView Rating Details
5/15/2017BTIG ResearchUpgradeNeutral -> Buy$39.00HighView Rating Details
4/3/2017William BlairReiterated RatingBuyLowView Rating Details
3/7/2017Janney Montgomery ScottUpgradeSell -> Neutral$31.00N/AView Rating Details
11/3/2016BenchmarkDowngradeBuy -> HoldN/AView Rating Details
8/3/2016JPMorgan Chase & Co.Reiterated RatingHold$25.00N/AView Rating Details
5/4/2016Leerink SwannReiterated RatingHoldN/AView Rating Details
(Data available from 2/18/2016 forward)

Earnings

Foundation Medicine (NASDAQ:FMI) Earnings History and Estimates Chart

Earnings by Quarter for Foundation Medicine (NASDAQ:FMI)

Foundation Medicine (NASDAQ FMI) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/7/2018($0.97)N/AView Earnings Details
2/20/2018($0.99)N/AView Earnings Details
11/1/2017Q3 2017($1.06)($0.90)$37.99 million$42.66 millionViewN/AView Earnings Details
8/1/2017Q2 2017($1.08)($1.24)$34.94 million$35.00 millionViewListenView Earnings Details
5/9/2017Q1 2017($1.02)($1.31)$29.07 million$26.32 millionViewListenView Earnings Details
2/22/2017Q416($0.96)($1.02)$29.23 million$28.80 millionViewListenView Earnings Details
11/2/2016Q316($0.88)($0.90)$28.70 million$29.43 millionViewN/AView Earnings Details
8/2/2016Q216($0.79)($0.84)$26.72 million$28.24 millionViewN/AView Earnings Details
5/3/2016Q116($0.72)($0.50)$25.20 million$30.40 millionViewN/AView Earnings Details
2/23/2016Q415($0.67)($0.55)$25.76 million$26.10 millionViewListenView Earnings Details
11/3/2015Q315($0.56)($0.60)$24.04 million$25.40 millionViewListenView Earnings Details
7/29/2015Q215($0.56)($0.98)$24.44 million$22.50 millionViewListenView Earnings Details
5/11/2015Q115($0.53)($0.59)$21.00 million$19.30 millionViewListenView Earnings Details
2/24/2015Q314($0.53)($0.47)$18.05 million$18.70 millionViewListenView Earnings Details
11/5/2014Q3($0.49)($0.46)$15.60 million$16.40 millionViewN/AView Earnings Details
8/12/2014Q214($0.50)($0.49)$13.39 million$14.50 millionViewN/AView Earnings Details
5/7/2014Q114($0.48)($0.44)$11.33 million$11.45 millionViewN/AView Earnings Details
2/25/2014Q413($0.43)($0.48)$9.01 million$9.66 millionViewN/AView Earnings Details
11/6/2013($0.51)($3.51)$6.92 million$8.20 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Foundation Medicine (NASDAQ:FMI) Earnings Estimates

2018 EPS Consensus Estimate: ($3.75)
2019 EPS Consensus Estimate: ($3.27)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.98)($0.98)($0.98)
Q2 20181($0.97)($0.97)($0.97)
Q3 20181($0.93)($0.93)($0.93)
Q4 20181($0.87)($0.87)($0.87)
Q1 20191($0.86)($0.86)($0.86)
Q2 20191($0.84)($0.84)($0.84)
Q3 20191($0.79)($0.79)($0.79)
Q4 20191($0.78)($0.78)($0.78)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Foundation Medicine (NASDAQ:FMI)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Foundation Medicine (NASDAQ FMI) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 2.70%
Institutional Ownership Percentage: 33.12%
Insider Trades by Quarter for Foundation Medicine (NASDAQ:FMI)
Institutional Ownership by Quarter for Foundation Medicine (NASDAQ:FMI)

Foundation Medicine (NASDAQ FMI) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/13/2018Steven J KafkaCOOSell29,791$61.55$1,833,636.05View SEC Filing  
2/7/2018Steven J KafkaCOOSell23,064$70.13$1,617,478.3261,361View SEC Filing  
2/7/2018Troy CoxCEOSell26,713$70.13$1,873,382.69224,345View SEC Filing  
1/29/2018Vincent A MillerInsiderSell4,400$75.00$330,000.0097,722View SEC Filing  
1/22/2018Vincent A MillerInsiderSell17,187$70.27$1,207,730.49110,509View SEC Filing  
1/17/2018Michael J PelliniDirectorSell37,288$64.55$2,406,940.40View SEC Filing  
1/17/2018Vincent A MillerInsiderSell14,755$65.31$963,649.05View SEC Filing  
1/16/2018Jason RyanCFOSell21,035$64.38$1,354,233.30View SEC Filing  
1/16/2018Robert W HessleinSVPSell18,021$64.30$1,158,750.30View SEC Filing  
1/16/2018Steven J KafkaCOOSell4,148$65.71$272,565.08View SEC Filing  
1/2/2018Jason RyanCFOSell2,336$64.00$149,504.00View SEC Filing  
1/2/2018Robert W. HessleinSVPSell1,864$64.00$119,296.00View SEC Filing  
1/2/2018Steven J. KafkaCOOSell157$64.00$10,048.00View SEC Filing  
1/2/2018Vincent A MillerInsiderSell2,349$64.00$150,336.0099,484View SEC Filing  
12/13/2017Evan/ Fa JonesDirectorSell1,400$62.05$86,870.0017,652View SEC Filing  
12/6/2017Evan/ Fa JonesDirectorSell6,500$60.66$394,290.0019,652View SEC Filing  
12/6/2017Steven J KafkaCOOSell5,774$58.57$338,183.1896,761View SEC Filing  
12/5/2017Jason RyanCFOSell21,726$61.26$1,330,934.7655,639View SEC Filing  
12/5/2017Vincent A MillerInsiderSell20,000$61.17$1,223,400.0099,984View SEC Filing  
11/2/2017Jason RyanCFOSell9,731$50.00$486,550.0052,601View SEC Filing  
10/13/2017Steven J KafkaCOOSell3,361$44.62$149,967.82View SEC Filing  
10/12/2017Jason RyanCFOSell1,152$45.05$51,897.60View SEC Filing  
10/2/2017Jason RyanCFOSell3,154$38.80$122,375.20View SEC Filing  
10/2/2017Michael J PelliniDirectorSell4,349$38.80$168,741.20View SEC Filing  
10/2/2017Robert W HessleinSVPSell2,165$38.80$84,002.00View SEC Filing  
10/2/2017Steven J KafkaCOOSell3,201$38.80$124,198.80View SEC Filing  
10/2/2017Vincent A MillerInsiderSell2,944$38.80$114,227.20View SEC Filing  
8/9/2017David DalyInsiderSell46,872$39.50$1,851,444.00163,133View SEC Filing  
8/9/2017Michael J PelliniDirectorSell30,000$39.52$1,185,600.00275,077View SEC Filing  
8/8/2017Krishna YeshwantDirectorSell4,800$40.01$192,048.005,786View SEC Filing  
8/4/2017Krishna YeshwantDirectorSell18,072$36.85$665,953.205,786View SEC Filing  
7/14/2017Steven J KafkaCOOSell11,781$39.15$461,226.1597,549View SEC Filing  
7/13/2017Jason RyanCFOSell5,084$39.77$202,190.6866,638View SEC Filing  
7/6/2017David DalyInsiderSell6,316$38.84$245,313.44View SEC Filing  
7/6/2017Jason RyanCFOSell6,683$38.84$259,567.72View SEC Filing  
7/6/2017Michael J. PelliniDirectorSell15,856$38.84$615,847.04View SEC Filing  
7/6/2017Robert W. HessleinSVPSell5,070$38.84$196,918.80View SEC Filing  
7/6/2017Steven J KafkaCOOSell19,708$38.93$767,232.44116,728View SEC Filing  
7/5/2017Steven J KafkaCOOSell12,310$38.98$479,843.80116,728View SEC Filing  
6/2/2017Jason RyanCFOSell5,573$40.00$222,920.0078,405View SEC Filing  
6/1/2017David DalyInsiderSell555$38.30$21,256.50View SEC Filing  
4/18/2017Jason RyanCFOSell503$34.55$17,378.6551,244View SEC Filing  
4/18/2017Steven J KafkaCOOSell4,405$34.55$152,192.75129,038View SEC Filing  
4/3/2017David DalyInsiderSell2,070$31.96$66,157.20View SEC Filing  
4/3/2017Michael J. PelliniDirectorSell1,700$31.96$54,332.00View SEC Filing  
4/3/2017Robert W. HessleinSVPSell1,233$31.96$39,406.68View SEC Filing  
4/3/2017Steven J. KafkaCOOSell2,157$31.96$68,937.72View SEC Filing  
3/16/2017Jason RyanCFOSell12,500$31.68$396,000.0056,230View SEC Filing  
3/16/2017Robert W HessleinSVPSell6,231$31.67$197,335.77104,305View SEC Filing  
3/8/2017Michael J PelliniDirectorSell40,000$34.30$1,372,000.00353,144View SEC Filing  
2/8/2017Steven J KafkaCOOSell10,415$23.24$242,044.60146,015View SEC Filing  
1/13/2017Jason RyanCFOSell1,777$19.00$33,763.0052,980View SEC Filing  
1/4/2017David DalyInsiderSell5,097$17.91$91,287.27View SEC Filing  
1/4/2017Jason RyanCFOSell4,665$17.74$82,757.10View SEC Filing  
1/4/2017Michael J. PelliniCEOSell14,637$17.67$258,635.79View SEC Filing  
1/4/2017Robert W. HessleinSVPSell4,682$17.74$83,058.68View SEC Filing  
1/4/2017Steven J. KafkaCOOSell8,390$17.72$148,670.80View SEC Filing  
12/1/2016David DalyInsiderSell564$19.95$11,251.80View SEC Filing  
11/22/2016Steven J KafkaCOOSell6,273$23.01$144,341.73103,009View SEC Filing  
10/20/2016Jason RyanCFOSell506$22.45$11,359.7059,422View SEC Filing  
10/20/2016Steven J KafkaCOOSell4,427$23.00$101,821.00101,550View SEC Filing  
10/4/2016David DalyInsiderSell2,045$23.65$48,364.25View SEC Filing  
10/4/2016Michael J. PelliniCEOSell2,629$23.65$62,175.85View SEC Filing  
10/4/2016Robert W. HessleinSVPSell1,220$23.65$28,853.00View SEC Filing  
10/4/2016Steven J. KafkaCOOSell2,135$23.62$50,428.70View SEC Filing  
9/20/2016Steven J KafkaCOOSell9,469$23.70$224,415.30108,112View SEC Filing  
8/19/2016Jason RyanCFOSell13,863$23.92$331,602.9661,148View SEC Filing  
7/5/2016David DalyInsiderSell5,008$17.76$88,942.08View SEC Filing  
7/5/2016Jason RyanCFOSell4,687$17.63$82,631.81View SEC Filing  
7/5/2016Michael J. PelliniCEOSell10,160$17.63$179,120.80View SEC Filing  
7/5/2016Robert W. HessleinSVPSell4,705$17.62$82,902.10View SEC Filing  
7/5/2016Steven J. KafkaCOOSell6,495$17.67$114,766.65View SEC Filing  
6/3/2016David DalyInsiderSell472$21.66$10,223.52114,458View SEC Filing  
4/1/2016Steven J KafkaCOOSell124$18.08$2,241.9241,226View SEC Filing  
4/1/2016Vincent A MillerInsiderSell356$18.08$6,436.4878,482View SEC Filing  
12/1/2015David DalyInsiderSell2,559$16.78$42,940.0245,631View SEC Filing  
11/13/2015Michael J PelliniCEOBuy9,100$16.43$149,513.00174,025View SEC Filing  
6/15/2015Krishna YeshwantDirectorSell183,860$32.98$6,063,702.80View SEC Filing  
4/7/2015Alexis BorisyDirectorSell234,542$50.00$11,727,100.00View SEC Filing  
4/7/2015Roche Holdings IncInsiderBuy15,604,288$50.00$780,214,400.00View SEC Filing  
4/7/2015Rock Ventures Lp ThirdMajor ShareholderSell3,976,278$50.00$198,813,900.00View SEC Filing  
3/5/2015Michael J PelliniCEOSell153,300$47.24$7,241,892.00View SEC Filing  
1/15/2015Steven J KafkaCOOSell15,000$48.38$725,700.00View SEC Filing  
1/12/2015Michael J PelliniCEOSell22,500$51.07$1,149,075.00View SEC Filing  
1/12/2015Robert W HessleinSVPSell7,000$52.11$364,770.00View SEC Filing  
1/12/2015Steven J KafkaCOOSell8,000$51.83$414,640.00View SEC Filing  
1/12/2015Vincent A MillerInsiderSell2,000$53.03$106,060.00View SEC Filing  
1/8/2015Robert W HessleinSVPSell4,000$23.03$92,120.00View SEC Filing  
12/29/2014Michael J PelliniCEOSell12,500$23.91$298,875.00View SEC Filing  
11/17/2014Jason RyanSVPSell3,541$24.90$88,170.90View SEC Filing  
11/14/2014Michael J PelliniCEOSell12,500$24.91$311,375.00View SEC Filing  
10/27/2014Jason RyanSVPSell2,360$25.00$59,000.00View SEC Filing  
10/27/2014Steven J KafkaCOOSell10,000$25.31$253,100.00View SEC Filing  
9/15/2014Jason RyanSVPSell2,361$21.92$51,753.12View SEC Filing  
8/18/2014Michael J PelliniCEOSell12,500$25.29$316,125.00View SEC Filing  
7/22/2014Steven J KafkaCOOSell10,000$27.14$271,400.00View SEC Filing  
7/15/2014Jason RyanSVPSell3,541$27.22$96,386.02View SEC Filing  
7/15/2014Vincent A MillerInsiderSell15,000$27.25$408,750.00View SEC Filing  
7/8/2014Robert W HessleinSVPSell4,000$27.22$108,880.00View SEC Filing  
7/2/2014Michael J PelliniCEOSell15,000$27.42$411,300.00View SEC Filing  
6/26/2014Jason RyanSVPSell1,180$25.00$29,500.00View SEC Filing  
6/26/2014Steven J KafkaCOOSell5,000$25.19$125,950.00View SEC Filing  
6/19/2014Steven J KafkaCOOSell5,000$24.46$122,300.00View SEC Filing  
6/16/2014Jason RyanSVPSell2,361$22.61$53,382.21View SEC Filing  
6/13/2014Krishna YeshwantDirectorSell1,300,000$22.40$29,120,000.00View SEC Filing  
6/5/2014Jason RyanSVPSell10,000$24.06$240,600.00View SEC Filing  
6/5/2014Steven J KafkaCOOSell4,500$24.19$108,855.00View SEC Filing  
5/6/2014Vincent MillerInsiderSell3,000$30.00$90,000.00117,000View SEC Filing  
4/16/2014Jason RyanSVPSell3,541$26.36$93,340.76View SEC Filing  
4/16/2014Vincent MillerInsiderSell30,000$26.86$805,800.00120,000View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Foundation Medicine (NASDAQ FMI) News Headlines

Source:
DateHeadline
-$1.01 Earnings Per Share Expected for Foundation Medicine Inc (FMI) This Quarter-$1.01 Earnings Per Share Expected for Foundation Medicine Inc (FMI) This Quarter
www.americanbankingnews.com - February 18 at 3:14 AM
Foundation Medicine Set For Material Upside, Cowen Says In Bullish InitiationFoundation Medicine Set For 'Material Upside,' Cowen Says In Bullish Initiation
finance.yahoo.com - February 16 at 8:13 AM
Insider Selling: Foundation Medicine Inc (FMI) COO Sells 29,791 Shares of StockInsider Selling: Foundation Medicine Inc (FMI) COO Sells 29,791 Shares of Stock
www.americanbankingnews.com - February 15 at 9:08 PM
Foundation Medicine (FMI) Now Covered by CowenFoundation Medicine (FMI) Now Covered by Cowen
www.americanbankingnews.com - February 15 at 12:23 PM
Adaptive Biotechnologies Appoints Veteran Molecular Diagnostics ... - Business Wire (press release)Adaptive Biotechnologies Appoints Veteran Molecular Diagnostics ... - Business Wire (press release)
www.businesswire.com - February 14 at 7:19 AM
Foundation Medicine Announces Timing for Fourth Quarter and Year-End 2017 Financial Results and Conference CallFoundation Medicine Announces Timing for Fourth Quarter and Year-End 2017 Financial Results and Conference Call
finance.yahoo.com - February 13 at 7:19 AM
Foundation Medicine (FMI) Scheduled to Post Earnings on TuesdayFoundation Medicine (FMI) Scheduled to Post Earnings on Tuesday
www.americanbankingnews.com - February 13 at 2:56 AM
Foundation Medicine (FMI) Downgraded by BidaskClub to HoldFoundation Medicine (FMI) Downgraded by BidaskClub to Hold
www.americanbankingnews.com - February 10 at 11:52 AM
Insider Selling: Foundation Medicine Inc (FMI) COO Sells 23,064 Shares of StockInsider Selling: Foundation Medicine Inc (FMI) COO Sells 23,064 Shares of Stock
www.americanbankingnews.com - February 9 at 6:18 PM
Foundation Medicine Inc (FMI) CEO Sells $1,873,382.69 in StockFoundation Medicine Inc (FMI) CEO Sells $1,873,382.69 in Stock
www.americanbankingnews.com - February 9 at 6:18 PM
FY2019 EPS Estimates for Foundation Medicine Inc Increased by William Blair (FMI)FY2019 EPS Estimates for Foundation Medicine Inc Increased by William Blair (FMI)
www.americanbankingnews.com - February 9 at 5:12 PM
Foundation Medicine (FMI) Stock Rating Upgraded by Zacks Investment ResearchFoundation Medicine (FMI) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - February 8 at 11:14 PM
Research Analysts Offer Predictions for Foundation Medicine Incs FY2017 Earnings (FMI)Research Analysts Offer Predictions for Foundation Medicine Inc's FY2017 Earnings (FMI)
www.americanbankingnews.com - February 8 at 8:00 AM
Commit To Purchase Foundation Medicine At $57.50, Earn 18.2% Annualized Using Options - NasdaqCommit To Purchase Foundation Medicine At $57.50, Earn 18.2% Annualized Using Options - Nasdaq
www.nasdaq.com - February 7 at 7:07 AM
Foundation Medicine Inc (FMI) Given Consensus Rating of "Hold" by BrokeragesFoundation Medicine Inc (FMI) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - February 4 at 1:32 AM
Foundation Medicine (FMI) Cut to "Sell" at Zacks Investment ResearchFoundation Medicine (FMI) Cut to "Sell" at Zacks Investment Research
www.americanbankingnews.com - January 31 at 11:58 PM
Foundation Medicine Inc (FMI) Insider Vincent A. Miller Sells 4,400 SharesFoundation Medicine Inc (FMI) Insider Vincent A. Miller Sells 4,400 Shares
www.americanbankingnews.com - January 31 at 6:24 PM
Foundation Medicine and European Organisation for Research and ... - Business Wire (press release)Foundation Medicine and European Organisation for Research and ... - Business Wire (press release)
www.businesswire.com - January 30 at 3:28 PM
Foundation Medicine and European Organisation for Research and Treatment of Cancer (EORTC) Announce Collaboration to Advance Precision Medicine Using Comprehensive Genomic Profiling to Facilitate Clinical Trial EnrollmentFoundation Medicine and European Organisation for Research and Treatment of Cancer (EORTC) Announce Collaboration to Advance Precision Medicine Using Comprehensive Genomic Profiling to Facilitate Clinical Trial Enrollment
finance.yahoo.com - January 30 at 7:09 AM
Foundation Medicine (FMI) Coverage Initiated by Analysts at Goldman Sachs GroupFoundation Medicine (FMI) Coverage Initiated by Analysts at Goldman Sachs Group
www.americanbankingnews.com - January 29 at 6:02 PM
Foundation Medicine (FMI) Lifted to "Buy" at BidaskClubFoundation Medicine (FMI) Lifted to "Buy" at BidaskClub
www.americanbankingnews.com - January 28 at 9:30 AM
Foundation Medicine Inc (FMI) Insider Vincent A. Miller Sells 17,187 SharesFoundation Medicine Inc (FMI) Insider Vincent A. Miller Sells 17,187 Shares
www.americanbankingnews.com - January 24 at 6:28 PM
Noteworthy Tuesday Option Activity: CVX, FMI, RYAM - NasdaqNoteworthy Tuesday Option Activity: CVX, FMI, RYAM - Nasdaq
www.nasdaq.com - January 24 at 5:16 AM
Steven J. Kafka Sells 4,148 Shares of Foundation Medicine Inc (FMI) StockSteven J. Kafka Sells 4,148 Shares of Foundation Medicine Inc (FMI) Stock
www.americanbankingnews.com - January 18 at 7:34 PM
Foundation Medicine Inc (FMI) Insider Sells $963,649.05 in StockFoundation Medicine Inc (FMI) Insider Sells $963,649.05 in Stock
www.americanbankingnews.com - January 18 at 7:00 PM
Foundation Medicine Inc (FMI) SVP Sells $1,158,750.30 in StockFoundation Medicine Inc (FMI) SVP Sells $1,158,750.30 in Stock
www.americanbankingnews.com - January 18 at 7:00 PM
Insider Selling: Foundation Medicine Inc (FMI) CFO Sells 21,035 Shares of StockInsider Selling: Foundation Medicine Inc (FMI) CFO Sells 21,035 Shares of Stock
www.americanbankingnews.com - January 18 at 7:00 PM
Insider Selling: Foundation Medicine Inc (FMI) Director Sells 37,288 Shares of StockInsider Selling: Foundation Medicine Inc (FMI) Director Sells 37,288 Shares of Stock
www.americanbankingnews.com - January 18 at 6:34 PM
Foundation Medicine and Pfizer Announce Broad Partnership to Develop Companion Diagnostics for Pfizers Oncology ... - Business Wire (press release)Foundation Medicine and Pfizer Announce Broad Partnership to Develop Companion Diagnostics for Pfizer's Oncology ... - Business Wire (press release)
www.businesswire.com - January 18 at 4:57 PM
Foundation Medicine, Pfizer Enter Into Broad Tie-up For Companion DiagnosticsFoundation Medicine, Pfizer Enter Into Broad Tie-up For Companion Diagnostics
www.nasdaq.com - January 16 at 9:31 AM
-$1.00 Earnings Per Share Expected for Foundation Medicine Inc (FMI) This Quarter-$1.00 Earnings Per Share Expected for Foundation Medicine Inc (FMI) This Quarter
www.americanbankingnews.com - January 15 at 5:38 AM
Foundation Medicine Inc (FMI) Given Average Rating of "Hold" by AnalystsFoundation Medicine Inc (FMI) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - January 10 at 1:44 AM
Insider Selling: Foundation Medicine Inc (FMI) COO Sells 157 Shares of StockInsider Selling: Foundation Medicine Inc (FMI) COO Sells 157 Shares of Stock
www.americanbankingnews.com - January 3 at 7:52 PM
Foundation Medicine Inc (FMI) SVP Robert W. Hesslein Sells 1,864 SharesFoundation Medicine Inc (FMI) SVP Robert W. Hesslein Sells 1,864 Shares
www.americanbankingnews.com - January 3 at 7:28 PM
Vincent A. Miller Sells 2,349 Shares of Foundation Medicine Inc (FMI) StockVincent A. Miller Sells 2,349 Shares of Foundation Medicine Inc (FMI) Stock
www.americanbankingnews.com - January 3 at 7:28 PM
Foundation Medicine Inc (FMI) CFO Jason Ryan Sells 2,336 SharesFoundation Medicine Inc (FMI) CFO Jason Ryan Sells 2,336 Shares
www.americanbankingnews.com - January 3 at 7:28 PM
What does Foundation Medicine Inc’s (NASDAQ:FMI) Balance Sheet Tell Us Abouts Its Future?What does Foundation Medicine Inc’s (NASDAQ:FMI) Balance Sheet Tell Us Abouts Its Future?
finance.yahoo.com - January 3 at 5:25 PM
Foundation Medicine to Present at the 36th Annual J.P. Morgan Healthcare ConferenceFoundation Medicine to Present at the 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 3 at 5:25 PM
Zacks: Analysts Expect Foundation Medicine Inc (FMI) to Announce -$1.00 EPSZacks: Analysts Expect Foundation Medicine Inc (FMI) to Announce -$1.00 EPS
www.americanbankingnews.com - December 29 at 9:30 AM
Foundation Medicine (FMI) Upgraded by BidaskClub to "Buy"Foundation Medicine (FMI) Upgraded by BidaskClub to "Buy"
www.americanbankingnews.com - December 28 at 4:56 PM
Foundation Medicine (FMI) Downgraded to Hold at BidaskClubFoundation Medicine (FMI) Downgraded to Hold at BidaskClub
www.americanbankingnews.com - December 24 at 8:15 AM
Foundation Medicine Inc (FMI) Receives Average Rating of "Buy" from BrokeragesFoundation Medicine Inc (FMI) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - December 16 at 1:52 AM
Insider Selling: Foundation Medicine Inc (FMI) Director Sells 1,400 Shares of StockInsider Selling: Foundation Medicine Inc (FMI) Director Sells 1,400 Shares of Stock
www.americanbankingnews.com - December 15 at 6:32 PM
ETFs with exposure to Foundation Medicine, Inc. : December 14, 2017ETFs with exposure to Foundation Medicine, Inc. : December 14, 2017
finance.yahoo.com - December 14 at 5:54 PM
Zacks: Brokerages Expect Foundation Medicine Inc (FMI) Will Post Quarterly Sales of $39.56 MillionZacks: Brokerages Expect Foundation Medicine Inc (FMI) Will Post Quarterly Sales of $39.56 Million
www.americanbankingnews.com - December 14 at 4:16 PM
Foundation Medicine (FMI) Upgraded to "Buy" at BidaskClubFoundation Medicine (FMI) Upgraded to "Buy" at BidaskClub
www.americanbankingnews.com - December 12 at 10:48 PM
Foundation Medicine Inc (FMI) Expected to Post Earnings of -$1.00 Per ShareFoundation Medicine Inc (FMI) Expected to Post Earnings of -$1.00 Per Share
www.americanbankingnews.com - December 12 at 5:06 AM
Foundation Medicine CEO talks the future of cancer treatm...Foundation Medicine CEO talks the future of cancer treatm...
finance.yahoo.com - December 11 at 5:34 PM
Foundation Medicine Inc (FMI) COO Sells $338,183.18 in StockFoundation Medicine Inc (FMI) COO Sells $338,183.18 in Stock
www.americanbankingnews.com - December 7 at 5:56 PM
Foundation Medicine Inc (FMI) Director Evan/ Fa Jones Sells 6,500 SharesFoundation Medicine Inc (FMI) Director Evan/ Fa Jones Sells 6,500 Shares
www.americanbankingnews.com - December 7 at 5:56 PM

SEC Filings

Foundation Medicine (NASDAQ:FMI) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Foundation Medicine (NASDAQ:FMI) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Foundation Medicine (NASDAQ FMI) Stock Chart for Sunday, February, 18, 2018

Loading chart…

This page was last updated on 2/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.